Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TSPO | P30536 | 7/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311196 | 0.99 | PTGDR2 (0.39) | MAPTTSPOPTGDR2CCR9TP53 | |
| SCHEMBL4307921 | 0.92 | CNR2 (0.38) | MAPTPTGDR2CCR9SRC | |
| SCHEMBL4315044 | 0.92 | PTGDR2 (0.37) | MAPTPTGDR2CCR9TP53SRC | |
| SCHEMBL4308974 | 0.91 | CNR2 (0.40) | MAPTPTGDR2CCR9SRC | |
| SCHEMBL4317696 | 0.91 | MAPT (0.38) | MAPTTSPOPTGDR2CCR9TP53 | |
| SCHEMBL4315275 | 0.90 | PTGDR2 (0.38) | MAPTTSPOPTGDR2CCR9TP53 | |
| SCHEMBL4303738 | 0.89 | MC4R (0.36) | MAPTPTGDR2CCR9 | |
| SCHEMBL4311886 | 0.88 | ALDH1A1 (0.38) | MAPTPTGDR2CCR9SRC | |
| SCHEMBL4307686 | 0.88 | PTGDR2 (0.38) | MAPTPTGDR2CCR9TP53SRC | |
| SCHEMBL4312789 | 0.87 | TP53 (0.40) | MAPTTSPOPTGDR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | MAPT 498/4885TSPO 859/4885PTGDR2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.